Isolation of human lymphocyte antigens class I-restricted cytotoxic T lymphocytes against autologous myeloma cells

Clinical Cancer Research

Volumn 5, Issue 3, 1999, Pages 705-709

  Pellat Deceunynck, Catherine ^a,c   Jego, Gaëtan ^a   Harousseau, Jean Luc ^a,b   Vié, Henri ^a   Bataille, Régis ^a  

^a INSTITUT DE BIOLOGIE   (France)

^b HÔTEL DIEU   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; HLA ANTIGEN CLASS 1; INTERLEUKIN 2;

ANTIGEN PURIFICATION; ANTIGEN RECOGNITION; ARTICLE; B LYMPHOBLAST; CELL CLONING; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EPSTEIN BARR VIRUS; HLA SYSTEM; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MULTIPLE MYELOMA; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0033067428     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Kyle, R. A., and Lust, J. A. Monoclonal gammopathies of undetermined significance. Semin. Hematol., 26: 176-200, 1989.
2. Bataille, R., and Harousseau, J-L. Multiple myeloma. Med. Progress, 336: 1657-1664, 1997.
3. Banchereau, J., and Rousset, F. Human B lymphocytes: phenotype, proliferation and differentiation. Adv. Immunol., 52: 125-262, 1992.
4. Foerster, J. Multiple Myeloma. In: G. R. Lee, T. C. Bithell, J. Foerster, J. W. Athens, and J. N. Lukens, (eds.), Wintrobe's, Clinical Hematology, 9th ed., Vol. 2, pp. 2219-2249. Philadelphia-London: Lea & Febiger, 1993.
5. Massaia, M., Borrione, P., Attisano, C., Barral, P., Beggiato, E., Montacchini, L., Bianchi, A., Boccadoro, M., and Pileri A. Dysregulated fas and Bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients. Blood, 85: 3679-3687, 1995.
6. + T cells in patients with multiple myeloma and paraproteinemia. Blood, 8: 3297-3306, 1996.
7. Yi, Q., Holm, G., and Lefvert, A. K. Idiotype-induced T cell stimulation requires antigen presentation in association with HLA-DR molecules. Clin. Exp. Immunol., 104: 359-365, 1996.
8. Takahashi, T., Makiguchi,. Y, Hinoda, Y., Kakiuchi, H., Nakagawa, N., Imai, K., and Yachi, A. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. J. Immunol., 153: 2102-2109, 1994.
9. Noto, H., Takahashi, T., Makiguchi, Y., Hayashi, T., Hinoda, Y., and Imai, K. Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin. Int. Immunol., 9: 791-798, 1997.
10. Puthier, D., Bataille, R., Barillé, S., Mellerin, M-P., Harousseau, J-L., Ponzio, A., Robillard, N., Wijdenes, J., and Amiot, M. Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone. Blood, 88: 4659-4666, 1996.
11. Pellat-Deceunynck, C., Bataille, R., Robillard, N., Harousseau, J-L., Rapp, M-J., Juge-Morineau, N., Wijdenes, J., and Amiot, M. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood, 84: 2597-2603, 1994.
12. Zhang, X. G., Gaillard, J-P., Robillard, N., Lu, Z. Y., Gu, Z. J., Jourdan, M., Boiron, J-M., Bataille, R., and Klein, B. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood, 83: 3654-3663, 1994.
13. Rebai, N., and Malissen, B. Structural and genetic analyses of HLA class I molecules using monoclonal xenoantibodies Tissue Antigens, 22: 107-117, 1983.
14. Smith, C. A., Ng, C. Y., Heslor, H. E., Holladay, M. S., Richardson, S., Turner, E. V., Loftin, S. K., Li, C., Brenner, M. K., and Rooney, C. M. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J. Hematother., 4: 73-79, 1995.
15. Gaschet, J., Trevino, M. A., Cherel, M., Vivien, R., Garcia-Sahuquillo, A., Hallet, M-M., Bonneville, M., Harousseau, J-L., Bragado, R., Milpied, N., and Vié, H. HLA-target antigens and T-cell receptor diversity of activated T cells invading the skin during acute graft-versus-host disease. Blood, 87: 2345-2353, 1996.
16. Agematsu, K., Kobata, T., Sugita, K., Hirose, T., Schlossman, S. F., and Morimoto, C. Direct cellular communications between CD45RO and CD45RA T cell subsets via CD27/CD70. J. Immunol., 154: 3627-3635, 1995.
17. Robillard, N., Jego, G., Pellat-Deceunynck, C., Pineau, D., Puthier, D., Mellerin, M-P., Barillé, S., Rapp, M-J., Harousseau, J-L., Amiot, M., and Bataille, R. CD28, a marker associated with tumoral expansion in multiple myeloma. Clin. Cancer Res., 4: 1521-1526, 1998.
18. Croft, M., Bradley, L. M., and Swain, S. L. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presentating cell types including resting B cells. J. Immunol., 152: 2675-2685, 1994.
19. Labarriere, N., Diez, E., Pandolfino, M-C., Viret, C., Guilloux, Y., Le Guiner, S., Fonteneau, J-F., Dreno, B., and Jotereau, F. Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription. J. Immunol., 158: 1238-1245, 1997.
20. Kwak, L. W., Taub, D. D., Duffey, P. L., Bensiger, W. I., Bryant, E. M., Reynolds, C. W., and Longo, D. L. Transfer of myeloma specific idiotype-specific immunity from an actively immunised marrow donor. Lancet, 345: 1016-1020, 1995.
21. Yi, Q., Dabadghao, S., Österborg, A., Bergenhart, S., and Holm, G. Myeloma bone marrow plasma cells: evidence for their capacity as antigen-presentating cells. Blood, 90: 1960-1967, 1997.
22. Attal, M., Harousseau, J-L., Stoppa, A-M., Sotto, J-J., Fuzibet, J-G., Rossi, J-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C., and Bataille, R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N. Engl. J. Med., 335: 91-97, 1996